Granted Patent
B2
US 12,522,835 · App. 19/194,571 · Granted Jan 13, 2026
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.
Claims (2)
1 . A composition that comprises a recombinant plasmid (RP) that comprises a sequence of nucleotides that is 100% identical to the full length of SEQ ID NO: 11.
2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 11, 2025
From: THOMPSON, BRADLEY G.; THOMPSON, JILL
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 073188/0270 →
Continuity (3)
References Cited (50)
US 20220220187A1
· Sabzevari et al.
· 2022
[cited by applicant]
CA 2721333A1
· 2009
[cited by applicant]
Yuasa et al. Low efficiency IDO2 enzymes are conserved in lower vertebrates, whereas higher efficiency IDO1 enzymes are dispensable. FEBS Journal 282 (2015) 2735-2745. (Year: 2015).
[cited by examiner]
Lam et al. 2015. siRNA Versus miRNA as Therapeutics for Gene Silencing. Molec. Ther. Nuc. Ac. 4:e252. doi: 10.1038/mtna.2015.23. (Year: 2015).
[cited by examiner]
Ying et al. 2008. The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function. Mol. Biotechnol. 38:257-268. doi: 10.1007/s12033-007-9013-8 (Year: 2008).
[cited by examiner]
Gorski, S., Vogel, J. & Doudna, J. RNA-based recognition and targeting: sowing the seeds of specificity. Nat Rev Mol Cell Biol 18, 215-228 (2017). (Year: 2017).
[cited by examiner]
Denzler R et al. Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression. Mol Cell. Nov. 3, 2016;64(3):565-579. doi: 10.1016/j.molcel.2016.09.027 (…
[cited by examiner]
Van den Berg, et al., pp. 1-12, Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016).
[cited by examiner]
NCBI Reference Sequence: NG_028155.1.
[cited by examiner]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery.” Nature reviews Drug discovery 18.5 (2019): 358-378.
[cited by applicant]
Barnum, Kevin J., and Matthew J. O'Connell. “Cell cycle regulation by checkpoints.” Cell cycle control: mechanisms and protocols (2014): 29-40.
[cited by applicant]
O'Brien et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation.” Frontiers in endocrinology 9 (2018): 402.
[cited by applicant]
Zhang et al. “The risks of miRNA therapeutics: in a drug target perspective.” Drug design, development and therapy (2021): 721-733.
[cited by applicant]
Zhang et al. “Functions of immune checkpoint molecules beyond immune evasion.” Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy (2020): 201-226.
[cited by applicant]
Kozomara et al. “miRBase: from microRNA sequences to function.” Nucleic acids research 47.D1 (2019): D155-D162.
[cited by applicant]
Jüppner, H. “Functional properties of the PTH/PTHrP receptor.” Bone 17.2 (1995): S39-S42.
[cited by applicant]
Ha et al. “Interspecies regulation of microRNAs and their targets.” Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1779.11 (2008): 735-742.
[cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112.
[cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023).
[cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010).
[cited by applicant]
GenBank EGF Sequence (2023).
[cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016.
[cited by applicant]
NCBI search results for Seq ID No. 5 (2024).
[cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023).
[cited by applicant]
GenBank EGFR Sequence (2023).
[cited by applicant]
Genbank FLT3 Sequence (2024).
[cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024).
[cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506.
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Ahmad et al .Adaptive selection in the evolution of programmed cell death-1 and its ligands in vertebrates. Aging (Albany NY). Feb. 11, 2020;12(4):3516-3557. (Year: 2020).
[cited by applicant]
NCBI Reference Sequence: NC_000009.12.
[cited by applicant]
Qiniou et al. Extraordinary diversity of the CD28/CTLA4 family across jawed vertebrates. Front. Immunol., Nov. 12, 2024. Sec. Comparative Immunology. vol. 15—2024. (Year: 2024).
[cited by applicant]
NCBI Reference Sequence: NG_011502.1.
[cited by applicant]
NCBI Reference Sequence: NR_030784.1.
[cited by applicant]
Vaddi et al. CTLA4 mRNA is downregulatA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients. Front. Immunol. Apr. 30…
[cited by applicant]
GenBank: LM608503.1. TPA:
[cited by applicant]
Broughton et al. (Molecular Cell, 64, 320-333, 2016).
[cited by applicant]